Kristina Burow

Kristina Burow is a Managing Director with ARCH Venture Partners. Ms. Burow is a director of Vividion, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome and Vir Biotechnology, and was a co-founder and director of Receptos (RCPT – acquired by Celgene). She participated in other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and Sapphire Energy (co-founder). Prior to joining ARCH in 2002, Ms. Burow was an Associate with the Novartis BioVenture Fund and was active in Chemistry Operations and Business Development at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.